Lys Therapeutics

Lys Therapeutics, first-in-class biotherapies against neurological diseases. Lys Therapeutics is a French biotech company developing innovative drugs to treat patients suffering from neurovascular or neurodegenerative disorders, including stroke and multiple sclerosis. Its main drug is a first-in-class monoclonal antibody, Glunozumab®, with an exclusive and groundbreaking mechanism of action. The clinical development of Glunozumab® biotherapy is of priority for Lys Therapeutics, as a game changer for patients suffering from neurological disorders with high unmet medical needs, for a potential major societal impact. In the physiopathology of neurological diseases such as stroke or multiple sclerosis, one protease called tissue plasminogen activator (tPA) triggers off-target toxicity via hyperactivation of both vascular and neuronal NMDA receptors (NMDAr), causing the disruption of the blood-brain and blood-spinal cord barriers, as well as strong neuronal excitotoxicity.